Short answer
Entrada Therapeutics, Inc. (TRDA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M (down 91.8% year over year) with net income of −$44M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- −91.8% YoY · −17.2% QoQ
- Net income
- −$44M
- −214.5% YoY · −2.4% QoQ
- Operating margin
- -2915.2%
- EPS (diluted)
- −$1.06
- −107.8% YoY · −1.0% QoQ
Source: XBRL data from the Entrada Therapeutics, Inc. (TRDA) Q3 2025 10-Q on SEC EDGAR. USD.
Entrada Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $1.6M, down $18.0M from $19.6M YoY
- Net loss $44.1M vs $14.0M YoY; operating margin -2,916.7% vs -110.7%
- ENTR-601-44 highest R&D spend $7.5M; ENTR-601-51 fastest increase to $2.8M from $0.1M
- Cash, equivalents and marketable securities $326.8M; funding expected through Q3 2027
- Near-term R&D expense increases; ENTR-601-44 data expected Q2 2026 and ENTR-601-45 data mid-2026
Risk Factors
- No newly triggered risk identified; filing text provides no comparison with the prior 10-K
- Liquidity risk: cash, cash equivalents and marketable securities expected to fund operations into third quarter 2027
- Regulatory risk: FDA may require additional preclinical studies before U.S. clinical trials, delaying or preventing initiation
- Operational risk: ENTR-601-44 safety, efficacy, supply or manufacturing problems could diminish the EEV Platform’s value
- Financial risk: $150.0 million at-the-market offering may not generate financing at acceptable prices or quantities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Entrada Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.